Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Completed · Phase 3

Conditions studied: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease

In brief

The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Key facts

Study ID

NCT03067441

Run by

Esperion Therapeutics, Inc.

People needed

1462

Starts

2017-02-03

Expected to finish

2019-11-05

Last updated by the study team

2021-03-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Successfully completed CLEAR Harmony (1002-040) parent study

You may not qualify if…

• Experienced a treatment-related SAE that led to study drug discontinuation in the CLEAR Harmony (1002-040) parent study.
• Medical condition requires lipid measurement and/or adjustment of background lipid-regulating therapy.

Where it is running

• Jedidiah Clinical Research — Tampa, Florida, United States
• L-MARC Research Center — Louisville, Kentucky, United States
• Sentral Clinical Research Services — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.